Better Health for All

Clearmind Medicine Inc. is a biotechnology company entirely focused on the discovery and development of novel psychedelic-derived therapeutics to address major health challenges such as Alcohol Use Disorder (AUD), obesity, metabolic syndrome, and PTSD. Pre-clinical trials for an obesity treatment (MEAI) showed reduced body weight, improved fatty liver, and normalized insulin sensitivity in rodents, with no observed adverse effects on motivation or well-being.

Pre-clinical trials for an AUD treatment demonstrated a significant suppressive effect on alcohol consumption and a high safety profile with no treatment-related histological changes in various organs. A Phase I/IIa clinical trial for CMND-100, an AUD treatment, has been initiated with the first participant dosed on June 30, 2025, to evaluate its safety and tolerability. The company holds 19 patent families, including 31 granted patents, related to its therapeutic compounds. The company's mental health services platform mentions secure and encrypted data and a banded charge system with a 15% administration fee.

Fair Money & Economic Opportunity

Clearmind Medicine Inc. is a biotechnology company focused on pharmaceutical research and development. Its core business involves the discovery, development, and commercialization of psychedelic-derived therapeutics, not financial services. As such, the company does not offer lending, deposit services, consumer credit products, or financial education programs.

Therefore, all Key Performance Indicators (KPIs) related to Fair Money & Economic Opportunity, which are designed for financial institutions, are not applicable to Clearmind Medicine Inc.

Honest & Fair Business

Clearmind Medicine Inc. has a Code of Business Conduct and Ethics that applies to all directors, officers, and employees, forbidding retaliation against those who report suspected misconduct.

The company's financial statements for the year ended October 31, 2023, were audited by two independent registered public accounting firms, Brightman Almagor Zohar & Co. and Saturna Group Chartered Professional Accountants LLP, indicating 100% audit coverage. However, the auditor's report included an explanatory paragraph regarding doubt about the company's ability to continue as a going concern. The company filed an amendment (Form 20-F/A) in March 2024 to revise a previous report related to retrospective adjustments for reverse share splits and a change in presentation currency, which constitutes one restatement in the past three years. The company's anti-corruption policy prohibits bribes, kickbacks, or other improper payments, but the evidence does not detail training frequency or effectiveness metrics. Furthermore, certain officers and directors of Clearmind Medicine Inc. also operate, manage, or are engaged as officers and/or directors of SciSparc Ltd., a related party with which the company has significant transactions, indicating potential conflicts of interest among board members.

Kind to Animals

Clearmind Medicine Inc. conducts pre-clinical trials using animal models for efficacy and toxicity assessments, including studies on rodents for cocaine craving, obesity, and acute/subacute toxicity.

While in-vitro methods were evaluated for cytotoxic and mutagenic effects, animal tests appear to be the primary method for complex endpoints. The company does not explicitly state an animal testing policy. The company collaborates with the Hebrew University of Jerusalem, where some studies involving animal testing were conducted, but there is no evidence of participation in multi-stakeholder initiatives specifically focused on developing industry-wide animal-free testing standards.

No War, No Weapons

The provided articles for Clearmind Medicine Inc. (CMND.US) focus exclusively on the company's biotechnology activities, including patent allowances for psychedelic treatments

, lobbying efforts to promote psychedelic-based therapies , and clinical trials for alcohol use disorder. No information or specific data points were found in any of the articles regarding revenue from arms or defense contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, board oversight of defense activities, export end-user certificates, lobbying related to arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance transparency, ethical red lines concerning weapons, exposure to controversial weapons, war-risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict zones. Therefore, no KPIs under the 'No War, No Weapons' value can be scored based on the evidence provided.

Planet-Friendly Business

The provided articles do not contain any specific, quantitative data points for Clearmind Medicine Inc. (CMND.US) regarding its environmental performance or sustainability initiatives.

Multiple articles explicitly state that sustainability data is unavailable or that no data is provided for the requested metrics, focusing instead on clinical trials, business strategy, and regulatory affairs. Therefore, no KPIs can be scored based on the evidence provided.

Respect for Cultures & Communities

The provided articles primarily detail Clearmind Medicine Inc.'s clinical trials, financial updates, corporate developments, and stock performance. There is no explicit information or quantitative data regarding formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, community complaint resolution times, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Consequently, no KPIs related to 'Respect for Cultures & Communities' can be scored based on the evidence provided.

Safe & Smart Tech

The company provides users with standard controls over their personal data, including the ability to unsubscribe from emails and request access to or correction of their data.

It also demonstrates compliance with relevant Canadian regulations, specifically the Controlled Drugs and Substances Act and Narcotic Control Regulations.